Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2

Corporate Breaking News

Home : Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2

Feb 15 2022	Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2
TAIZHOU, China, Feb. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (Recbio), a China-based company focused on the development of innovative vaccines for major diseases, announced preclinical data of its subsidiary Wuhan Recogen Biotechnology Co., Ltd. (Recogen) on...


Source:https://www.prnewswire.com:443/news-releases/recbio-provides-updates-on-first-lyophilized-mrna-vaccine-and-pre-clinical-data-showing-long-term-stability-and-strong-immunogenicity-against-sars-cov-2-301482185.html

Related News
» OM SYSTEM Brings Heavyweight Specs to its New OM-1 Micro Four Thirds Camera; More Info at B&H » Judge says he'll dismiss Sarah Palin's libel suit against New York Times